CONTEXT: Clinical trials of phosphodiesterase type 5 inhibitors (PDE5-Is) have consistently
demonstrated a significant reduction in lower urinary tract symptoms (LUTS) and small …

Lower urinary tract symptoms (LUTS), comprising storage (such as urinary incontinence and
urinary frequency), voiding, and postmicturition symptoms, are highly prevalent conditions …

Purpose: Activators of soluble guanylyl cyclase are of potential interest as treatment for
cardiovascular diseases but to our knowledge they have never been proposed to treat …

Within the urinary tract, β-adrenergic receptors (AR) are found largely on smooth muscle
cells but are also present, at least in the bladder, in the urothelium and on afferent nerves …

Abstract β-Adrenoceptor stimulation can enhance the storage function of the urinary bladder
by acting on detrusor smooth muscle tone, mediator release from the urothelium and/or …

Introduction: Pelvic hypoperfusion caused by atherosclerosis has been proposed as a cause
of lower urinary tract dysfunction including overactive bladder syndrome (OAB). Limited data …

Aims To evaluate the effects of the beta‐3 adrenoceptor agonist, mirabegron in a mouse
model of detrusor overactivity induced by obesity. Methods C57BL/6 male mice were fed …

Purpose Metabolic syndrome and obesity have been advocated to be risk factors for the
development of overactive bladder (OAB). Additionally, insulin resistance is the underlying …

While animal studies have suggested an association between the presence of hypertension
and the presence and/or severity of overactive bladder syndrome (OAB) symptoms, little …

Patients with sickle cell disease (SCD) display an overactive bladder (OAB). Intravascular
hemolysis in SCD is associated with various severe SCD complications. However, no …